26
|
Strandvik B, Walkowiak J, Drzymala-Czyz S, Colombo C, Alicandro G, Bakkeheim E, Badolato R, Hansen C. P059 A double-blind randomised multi-centre European study of linoleic acid supplementation for one year in patients with cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01086-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
McClenaghan E, Cosgriff R, Brownlee K, Ahern S, Burgel PR, Byrnes C, Colombo C, Corvol H, Cheng S, Daneau G, Elbert A, Faro A, Goss C, Gulmans V, Gutierrez H, de Monestrol I, Jung A, Nährlich L, Kashirskaya N, Marshall B, McKone E, Middleton P, Mondejar-Lopez P, Pastor-Vivero M, Padoan R, Rizvi S, Ruseckaite R, Salvatore M, Stephenson A, da Silva Filho L, Melo J, Zampoli M, Abdrakhmanov O, Harutyunyan S, Carr S. P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study. J Cyst Fibros 2021. [PMCID: PMC8192143 DOI: 10.1016/s1569-1993(21)01110-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Rosazza C, Bischetti G, Sciarrabba C, Daccò V, Nazzari E, Russo M, Colombo C. P038 An Italian centre experience with elexacaftor-tezacaftor-ivacaftor therapy in cystic fibrosis patients with advanced lung disease. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01065-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Colombo C, Alicandro G, Daccó V, Gagliano V, Morlacchi L, Casciaro R, Pisi G, Francalanci M, Cavallo A, Poli P, Folino A, Messore B, Cristadoro S, Leonetti G, Maschio M, Lucca F, Cipolli M. P134 SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multi-centre prospective study with a control group. J Cyst Fibros 2021. [PMCID: PMC8192163 DOI: 10.1016/s1569-1993(21)01160-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Palazzari E, Buonadonna A, Lauretta A, Navarria F, Ongaro E, Foltran L, Innocente R, Belluco C, Ubiali P, Canzonieri V, Urbani M, Colombo C, Bertola G, De Paoli A. PO-1112: Total neoadjuvant therapy in high risk rectal cancer: a feasibility pilot study. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01129-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Botteon A, Yiming J, Prati S, Sciutto G, Realini M, Colombo C, Castiglioni C, Matousek P, Conti C. Non-invasive characterisation of molecular diffusion of agent into turbid matrix using micro-SORS. Talanta 2020; 218:121078. [DOI: 10.1016/j.talanta.2020.121078] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 04/20/2020] [Accepted: 04/22/2020] [Indexed: 11/16/2022]
|
32
|
Fabbri A, Parker L, Colombo C, Mosconi P, Barbara G, Lau E, Kroeger CM, Lunny C, Salzwedel DM, Mintzes B. Industry funding of patient groups: a systematic review. Eur J Public Health 2020. [DOI: 10.1093/eurpub/ckaa165.805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Patient groups play an important role in health care and policy. Concerns have been raised about the financial ties between the pharmaceutical industry and patient groups, because of potential threats to the groups' independence. We conducted a systematic review to synthesise studies that explored pharmaceutical or medical device industry funding of patient groups.
Methods
We searched Medline, Embase, Web of Science, Scopus and Google Scholar (from inception to January 2018). We included observational studies reporting at least one of the following outcomes: prevalence of industry funding; proportion of industry funded patient groups which disclosed information about this funding; association between industry funding and organisational positions on health and policy issues. We carried out duplicate independent data extraction and assessed study quality.
Results
26 cross-sectional studies were included. Fifteen studies assessed the prevalence of industry funding, which ranged from 20% (12/61) to 83% (86/104). The proportion of patient groups which disclosed funding information on their websites was low (27% [95% CI: 24%-31%]). Few patient groups had formal policies governing corporate sponsorship (range from 2% (2/125) to 64% (175/274)). Among the few studies examining funding status versus organisational position, industry sponsored groups tend to hold positions consistent with sponsors' interests.
Conclusions
We found widespread indications of industry funding of patient groups. Transparency of funding is inadequate and the prevalence of policies governing corporate sponsorship is low. Research on policy impact is still limited. Considering the important role that patient groups play in health, strategies to prevent biases that may favour commercial interests above those of patients need to be implemented.
Key messages
Industry funding of patient groups is common in high income countries. Transparency of funding is inadequate and the prevalence of policies governing corporate sponsorship is low. Considering the important role that patient groups play in health care and policy, strategies to prevent biases that may favour commercial interests above those of patients need to be implemented.
Collapse
|
33
|
Martin-Tellez KS, van Houdt WJ, van Coevorden F, Colombo C, Fiore M. Isolated limb perfusion for soft tissue sarcoma: Current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 2020; 88:102058. [PMID: 32619864 DOI: 10.1016/j.ctrv.2020.102058] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Accepted: 06/11/2020] [Indexed: 12/15/2022]
Abstract
Soft tissue sarcomas constitute 1% of adult malignant tumors. They are a heterogeneous group of more than 50 different histologic types. Isolated limb perfusion is an established treatment strategy for locally advanced sarcomas. Since its adoption for sarcomas in 1992, after the addition of TNFα, few modifications have been done and although indications for the procedure are essentially the same across centers, technical details vary widely. The procedures mainly involves a 60 min perfusion with melphalan and TNFα under mild hyperthermia, achieving a limb preservation rate of 72-96%; with an overall response rates from 72 to 82.5% and an acceptable toxicity according to the Wieberdink scale. The local failure rate is 27% after a median follow up of 14-31 months compared to 40% of distant recurrences after a follow up of 12-22 months. Currently there is no consensus regarding the benefit of ILP per histotype, and the value of addition of radiotherapy or systemic treatment. Further developments towards individualized treatments will provide a better understanding of the population that can derive maximum benefit of ILP with the least morbidity.
Collapse
|
34
|
Muzza M, Colombo C, Pogliaghi G, Karapanou O, Fugazzola L. Molecular markers for the classification of cytologically indeterminate thyroid nodules. J Endocrinol Invest 2020; 43:703-716. [PMID: 31853887 DOI: 10.1007/s40618-019-01164-w] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 12/11/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND The diagnosis of indeterminate lesions of the thyroid is a challenge in cytopathology practice. Indeed, up to 30% of cases lack the morphological features needed to provide definitive classification. Molecular tests have been developed to assist in the diagnosis of these indeterminate cases. The first studies dealing with the preoperative molecular evaluation of FNA samples focused on the analysis of BRAFV600E or on the combined evaluation of two or three genetic alterations. The sensitivity of molecular testing was then improved through the introduction of gene panels, which became available for clinical use in the late 2000s. Two different categories of molecular tests have been developed, the 'rule-out' methods, which aim to reduce the avoidable treatment of benign nodules, and the 'rule-in' tests that have the purpose to optimize surgical management. The genetic evaluation of indeterminate thyroid nodules is predicted to improve patient care, particularly if molecular tests are used appropriately and with the awareness of their advantages and weaknesses. The main disadvantage of these tests is the cost, which makes them rarely used in Europe. To overcome this limitation, customized panels have been set up, which are able to detect the most frequent genetic alterations of thyroid cancer. CONCLUSIONS In the present review, the most recent available versions of commercial molecular tests and of custom, non-commercial panels are described. Their characteristics and accuracy in the differential diagnosis of indeterminate nodules, namely Bethesda classes III (Atypical follicular lesion of undetermined significance, AUS/FLUS) and IV (Suspicious for follicular neoplasm, FN/SFN) are fully analyzed and discussed.
Collapse
|
35
|
Mariani A, Carta F, Gambazza S, Brivio A, Bassotti G, Gesuele A, Caverni E, Colombo C. ePS1.10 Prevalence of female urinary incontinence in the paediatric Cystic Fibrosis Centre of Milan. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30290-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Nazzari E, Daccò V, Bulfamante A, Borzani I, Corti F, Colombo C. P215 Safety and efficacy of lumacaftor/ivacaftor treatment in cystic fibrosis patients aged 9–11 years: preliminary data. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30549-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Colombo C, Alicandro G, Evans H, Oliver M, Ooi C, Alghisi F, Kashirskaya N, Kondratyeva E, Ramm G, de Monestrol I, Padoan R, Asherova I, Lindblad A. WS03.2 A multicentre cohort study on ursodeoxycholic acid and liver disease associated with cystic fibrosis. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30178-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
38
|
Boon M, Calvo-Lerma J, Claes I, Havermans T, Asseiceira I, Bulfamante A, Garriga M, Masip E, van Schijndel BAM, Fornes V, Barreto C, Colombo C, Crespo P, Vicente S, Janssens H, Hulst J, Witters P, Nobili R, Pereira L, Ruperto M, Van der Wiel E, Mainz JG, De Boeck K, Ribes-Koninckx C. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis. J Cyst Fibros 2020; 19:562-568. [PMID: 32335023 DOI: 10.1016/j.jcf.2020.04.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 04/02/2020] [Accepted: 04/04/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency (PI), leading to fat malabsorption, malnutrition, abdominal discomfort and impaired growth. Pancreatic enzyme replacement therapy (PERT) is effective, but evidence based guidelines for dose adjustment are lacking. A mobile app for self-management of PERT was developed in the context of the HORIZON 2020 project MyCyFAPP. It contains an algorithm to calculate individual PERT-doses for optimal fat digestion, based on in vitro and in vivo studies carried out in the same project. In addition, the app includes a symptoms diary, educational material, and it is linked to a web tool allowing health care professionals to evaluate patient's data and provide feedback. METHODS A 6-month open label prospective multicenter interventional clinical trial was performed to assess effects of using the app on gastro-intestinal related quality of life (GI QOL), measured by the CF-PedsQL-GI (shortened, CF specific version of the Pediatric Quality of Life Inventory, Gastrointestinal Symptoms Module). RESULTS One hundred and seventy-one patients with CF and PI between 2 and 18 years were recruited at 6 European CF centers. Self-reported CF-PedsQL-GI improved significantly from month 0 (M0) (84.3, 76.4-90.3) to month 6 (M6) (89.4, 80.35-93.5) (p< 0.0001). Similar improvements were reported by parents. Lower baseline CF-PedsQL-GI was associated with a greater improvement at M6 (p < 0.001). CONCLUSIONS The results suggest that the MyCyFAPP may improve GI QOL for children with CF. This tool may help patients to improve self-management of PERT, especially those with considerable GI symptoms.
Collapse
|
39
|
Seghi F, Vai B, Barbini B, Attanasio F, Benedetti F, Colombo C. P82 Neurobiologic and clinical correlates of low-frequency TMS over the left DorsoLateral Prefrontal Cortex in Manic Episode. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Attanasio F, Barbini B, Seghi F, Prestifilippo D, Zanardi R, Cavallini C, Colombo C. P104 Treatment resistant depression: rTMS combined with Light Therapy, a novel approach. Clin Neurophysiol 2020. [DOI: 10.1016/j.clinph.2019.12.215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
41
|
Delmonte D, De Santis C, Brioschi S, Barbini B, Colombo C. Haloperidol, risperidone and quetiapine in the treatment of acute severe manic episode in bipolar disorder: The experience at the mood disorder unit in Milan. Eur Psychiatry 2020. [DOI: 10.1016/j.eurpsy.2016.01.146] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
IntroductionPatients affected by severe manic episode, often with delusional symptoms, are commonly treated with a combination of mood stabilizers, antipsychotics and other sedatives. The choice of a specific drug, dose and term is still debated.ObjectivesA naturalistic study on a sample of 84 inpatients affected by acute severe mania treated with a combination therapy.AimsTo compare efficacy and tolerability of haloperidol/risperidone/quetiapine in association with lithium and/or valproate.MethodsEighty-four bipolar inpatients affected by a manic episode according to DSM-5 criteria. Drugs administered according to our best practice. Clinical course weekly monitored with Young Mania Rating Scale (YMRS) for 4weeks. Extrapiramidal side effects (EPSE) monitored with Saint Hans Rating Scale (SHRS).ResultsTwenty-five men (29.76%) and 59 women (70.24%); mean age 43.37 ± 13.58 years. Mean YMRS score T0 40.27 ± 9.04. Forty-one patients (48.81%) treated with haloperidol (3.4 mg/die); 16 (19.05%) with risperidone (4.3 mg/die); 27 (32.14%) with quetiapine (438 mg/die). The 3 groups showed no difference regarding clinical characteristics and YMRS basal scores. Chi2 analysis confirmed an higher response rate (50% of reduction of YMRS final score compared to T0) with haloperidol (χ2 = 14.88; P = 0.00). The repeated-measures model analysis showed a significant decrease (P < 0.05) in YMRS scores in haloperidol vs. risperidone vs. quetiapine patients for all time points from second week. No statistical difference for EPSE was found.ConslusionsWe suggest that haloperidol could be advisable in the treatment of severe mania, with rapid efficacy, even with low doses. Occurrence of EPSE was not considerable during the acute treatment. Studies with a larger sample size, randomization, fixed doses, double blind design are needed.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
42
|
Zanatta E, Colombo C, D’Amico G, d’Humières T, Dal Lin C, Tona F. Inflammation and Coronary Microvascular Dysfunction in Autoimmune Rheumatic Diseases. Int J Mol Sci 2019; 20:ijms20225563. [PMID: 31703406 PMCID: PMC6888405 DOI: 10.3390/ijms20225563] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 10/31/2019] [Accepted: 11/05/2019] [Indexed: 02/07/2023] Open
Abstract
Autoimmune rheumatic diseases (ARDs) form a heterogeneous group of disorders that include systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIMs), and systemic vasculitis. Coronary microvascular dysfunction (CMD) is quite common in patients with ARDs and is linked to increased cardiovascular morbidity and mortality. Inflammation plays a crucial role in the pathogenesis of both accelerated atherosclerosis and CMD in ARDs, especially in patients affected by SLE and RA. In this regard, some studies have highlighted the efficacy of immunosuppressants and/or biologics in restoring CMD in these patients. By contrast, the role of inflammation in the pathogenesis of CMD-SSc appears to be much less relevant compared to endothelial dysfunction and microvascular ischemia, with calcium-channel blockers providing some benefits. Few studies have endeavored to assess the occurrence of CMD in IIMs and systemic vasculitis, thus warranting further investigations. The present review summarizes the current evidence on the occurrence of CMD in ARDs, focusing on the role of inflammation and possible therapeutic approaches.
Collapse
|
43
|
Rossini D, Pagani F, Pellino A, Dell’Aquila E, Liscia N, Bensi M, Germani M, Masi G, Moretto R, Santini D, Salvatore L, Scartozzi M, Lonardi S, Zucchelli G, Puglisi F, Vannini F, Colombo C, Falcone A, Pietrantonio F, Cremolini C. Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Claut L, Zazzeron L, Castellazzi L, Alicandro G, Porcaro L, Seia M, Colombo C. WS20-4 Cystic fibrosis screen-positive, inconclusive diagnosis (CF-SPID): diagnostic and clinical data from a cohort of screened infants. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30237-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
45
|
Di Cicco M, Di Pasquale D, Borin M, Colombo C. P233 Cystic fibrosis sinus score for paranasal sinuses complications of cystic fibrosis: a 3-year long experience. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30526-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
46
|
Boon M, Calvo-Lermo J, Claes I, Havermans T, Fornes V, Asseiceira I, Bulfamente A, Garriga M, Massip E, Walet S, Barreto C, Colombo C, Crespo P, Janssens H, Ruperto M, Hulst J, Nobili R, Pereira L, Van der Wiel E, Vicente S, De Boeck K, Ribes-Koninckx C. ePS5.08 MyCyFAPP project: use of a mobile application for self-management of PERT improves gastrointestinal related quality of life in children with cystic fibrosis. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30286-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
47
|
Giana A, Valmarana L, Valmarana R, Bulfamante A, Zazzeron L, Corti F, Nobili R, Bellapi S, Colombo C. P334 A program to manage feeding problems and malnutrition in toddlers and children with cystic fibrosis: how to use at best the cystic fibrosis core team expertise to save money and suffering. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30626-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
48
|
Pasquali S, Colombo C, Bottelli S, Verderio P, Broto J, Lopez--Pousa A, Ferrari S, Poveda A, Quagliolo V, Gronchi A. The sarculator predicted risk of distant metastasis and overall survival in patients with high-risk soft tissue sarcoma treated with perioperative chemotherapy in a randomised controlled trial. Eur J Surg Oncol 2018. [DOI: 10.1016/j.ejso.2018.07.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
49
|
Castellani C, Colombo C, van der Ent C, Simmonds N, Kinnman N, Hassan M, DeSouza C, Kaviya A. WS05.4 Clinical effectiveness results from the first interim analysis of the VOCAL study; an observational study of ivacaftor in patients with cystic fibrosis and selected non-G551D gating mutations. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30146-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
50
|
Calvo-Lerma J, Hulst J, Boon M, Masip E, Fornés-Ferrer V, Garriga M, Colombo C, Crespo P, Roca M, Woodcock S, Van der Wiel E, Claes I, de Boeck K, Ribes-Koninckx C, MyCyFAPP. WS03.6 A first approach for an evidence-based method to adjust PERT: in vivo validation of the in vitro model. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30136-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|